Skip to content

Hero image: A midlife woman speaking comfortably with a menopause specialist in a private consultation

All insights

Transitions and Sexual Health

Genitourinary Syndrome of Menopause: Treat the Tissue, Symptoms and Context

10 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based guide to GSM symptoms, diagnosis, vaginal estrogen, nonhormonal options, recurrent urinary concerns and cancer-related decisions.

Evidence at a glance

68 publications

effectiveness or harms evidence synthesized for the 2025 AUA, SUFU and AUGS guideline

The guideline also mapped additional nonhormonal evidence and concluded that local low-dose vaginal estrogen has the most robust evidence base, while still noting inconsistency and imprecision for some outcomes. [2]

The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause

GSM includes vulvar, vaginal, sexual and urinary symptoms

Genitourinary syndrome of menopause describes symptoms and physical changes associated with declining estrogen and androgen effects on the vulva, vagina, urethra and bladder. Symptoms can include dryness, burning, irritation, pain with sex, reduced lubrication, urinary urgency, dysuria and recurrent urinary infections. [2] Not every symptom must be present.

Unlike hot flushes, untreated tissue symptoms often persist or progress. They can affect intimacy, exercise, sleep, continence care and willingness to attend examinations. The term GSM connects tissues that are often discussed separately, but diagnosis must still rule out infection, dermatologic disease, pelvic-floor dysfunction, vulvodynia, malignancy and medication effects.

  • Ask about vulvar and urinary symptoms together.
  • Use the person's own priorities to define burden.
  • Do not assume pain with sex is inevitable with age.
  • Investigate bleeding after menopause promptly.

Diagnosis is clinical and should not rely on one examination sign

The 2025 AUA, SUFU and AUGS guideline supports diagnosis from symptoms, with or without related physical findings, after considering alternative or coexisting causes. [2] Examination may show pallor, tissue fragility, reduced elasticity or introital narrowing, but severity of visible change and symptom burden do not always match.

A respectful assessment asks permission, explains each step and stops when requested. Urinalysis, infection testing, vulvar evaluation or other testing is chosen according to the presentation. Persistent focal lesions, unexplained bleeding, discharge, severe pain or treatment failure should prompt reassessment rather than automatic escalation of a presumed GSM treatment.

  • Clarify whether pain is superficial, deep or both.
  • Review bladder symptoms and infection history.
  • Assess pelvic-floor tenderness when indicated.
  • Use trauma-informed examination techniques.

Nonhormonal options can be useful, but products serve different roles

Lubricants reduce friction during sexual activity, while vaginal moisturizers are used regularly to support comfort. NICE recommends nonhormonal moisturizers or lubricants for people who prefer them or cannot use vaginal estrogen. [1] Products should be fragrance-free and chosen for comfort, condom compatibility and individual sensitivity.

Pelvic-floor physical therapy can help when muscle overactivity, guarding or pain persists alongside tissue symptoms. Sexual counseling may address fear, communication and changes in arousal without implying that symptoms are psychological. Nonhormonal treatment can be combined with local hormonal treatment. Energy-based vaginal devices should not be presented as established first-line care because long-term comparative evidence is insufficient.

  • Use lubricant for friction and moisturizer for ongoing comfort.
  • Stop products that burn or irritate.
  • Treat pelvic-floor overactivity as a coexisting contributor.
  • Ask for evidence and regulatory status before device procedures.

Local low-dose vaginal estrogen has the strongest evidence base

The 2025 joint guideline recommends offering local low-dose vaginal estrogen for vulvovaginal discomfort, dryness or dyspareunia. [3] Cream, tablet, insert and ring formulations differ in application and preference. Treatment is local, although small systemic absorption can occur. Choice should be individualized rather than based on a claim that one formulation is universally superior.

The guideline notes mixed effects in some placebo-controlled outcomes but supports use because of overall effectiveness and a high safety margin. [3] NICE also recommends vaginal estrogen alone or with nonhormonal products. [1] Symptoms should be reviewed after initiation, with technique, adherence, diagnosis and coexisting pain considered if response is incomplete.

  • Choose formulation through shared decision making.
  • Review application technique and comfort.
  • Reassess persistent pain rather than increasing treatment blindly.
  • Discuss ongoing use because symptoms may return after stopping.

Breast cancer history requires individualized, multidisciplinary decisions

NICE recommends nonhormonal moisturizers or lubricants first for people with a personal history of breast cancer, and considering vaginal estrogen when symptoms continue. For those taking an aromatase inhibitor, it recommends working with a breast-cancer specialist. [1] The guideline explicitly states that the effect on recurrence risk is unknown.

This is a preference-sensitive decision. The discussion should include symptom severity, recurrence risk, cancer treatment, nonhormonal response, systemic absorption, uncertainty and quality of life. A blanket prohibition and blanket reassurance both exceed the evidence. Clear documentation and coordination among the patient, oncology and menopause or urogenital specialists improve continuity.

  • Review current endocrine cancer therapy.
  • State what is known and unknown about recurrence.
  • Consider symptom burden and nonhormonal response.
  • Make the decision with oncology when appropriate.

Follow-up should test whether the original problem was solved

A useful review asks about dryness, irritation, pain, sexual function, urinary symptoms, infections, bleeding and product acceptability. Recurrent urinary symptoms should be culture-confirmed when appropriate because urgency or burning does not always mean bacterial infection. NICE links GSM care with its recurrent urinary-tract infection guidance. [1]

Prasterone or ospemifene may be considered in selected circumstances when local estrogen or nonhormonal approaches are ineffective, not tolerated or impractical. [1] Each has distinct contraindications, systemic exposure and evidence. The aim is comfortable tissue and restored function on a plan the person can sustain, not normalization of an examination appearance.

  • Define the symptom that matters most before treatment.
  • Confirm suspected recurrent infections appropriately.
  • Review unexpected bleeding without delay.
  • Adapt the regimen to ability, preference and response.

What the evidence cannot yet answer

  • There is no universally agreed minimum number or combination of symptoms required for GSM diagnosis.
  • Trials vary in formulation, dose, outcome scale and follow-up, producing inconsistency for some effects.
  • Evidence for breast-cancer recurrence with vaginal estrogen remains observational and uncertain, particularly with aromatase inhibitors.
  • Long-term effectiveness and safety evidence for energy-based devices is insufficient for routine first-line use.

Questions worth taking into care

  1. Could infection, vulvar disease, pelvic-floor dysfunction or another condition explain my symptoms?
  2. Would a lubricant, moisturizer, local estrogen or combination best match my goals?
  3. How does my cancer and medication history change the decision?
  4. What symptoms or bleeding require earlier review?
  5. When will we assess response and reconsider the diagnosis?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Menopause: Identification and Management

    National Institute for Health and Care Excellence · 2024

  2. [2]
    The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause

    American Urological Association, SUFU and AUGS · 2025

  3. [3]
    Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline

    American Urological Association, SUFU and AUGS · 2025

  4. [4]
  5. [5]
  6. [6]
Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.